Tag: BioSig

BioSig Technologies to Ring NASDAQ Opening Bell on November 13, 2018

Santa Monica, CA, Nov. 12, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today its Founder, Chairman & CEO […]

BioSig Technologies to Present at the 4th Annual Dawson James Small Cap Growth Conference

Santa Monica, CA, Oct. 29, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that it will be presenting […]

BioSig Technologies Retains Gilmartin Group for Investor Relations

Santa Monica, CA, Sept. 24, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that it has retained Gilmartin Group for strategic investor relations […]

BioSig Technologies to Commence Trading on the Nasdaq

Santa Monica, CA, Sept. 19, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB:BSGM, OTCQB:BSGMD), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced that its shares of common stock have been approved for […]

BioSig Technologies, Inc. Announces 1-for-2.5 Reverse Stock Split for Pending Uplist to Nasdaq

Santa Monica, CA, Sept. 10, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM, OTCQB: BSGMD) (“BioSig” or the “Company”),  a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company […]

BioSig Technologies Issues Shareholder Letter

Santa Monica, CA, Sept. 11, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB:BSGM, OTCQB:BSGMD) a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has issued their September 2018 letter […]

BioSig Technologies to Present at the MicroCap Leadership Summit

Santa Monica, CA, Aug. 22, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it has been selected to present at the third annual […]

BioSig Technologies Announces FDA 510(k) Clearance for PURE EP System

Santa Monica, CA, Aug. 14, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), announced that the Company has received 510(k) clearance for its first product, PURE EP System, from the U.S. Food and Drug Administration (FDA). The non-invasive PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring […]

BioSig Technologies Completes Private Placement

Santa Monica, CA, Aug. 13, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company closed a private placement of $4,281,000. Combined with the […]